David Henry Jablonski, M.D North Mills Avenue Orlando, FL 32803

Similar documents
Jeffrey Richard Thill, M.D North Mills Avenue Orlando, FL 32803

Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC

Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122

Richard J. Ingebretsen, M.D., Ph.D.

Curriculum Vitae, Conrad O. Beckles, M.S., L.M.H.C., Ph.D.

09/84-06/88 BA, Chemistry Robert D. Clark Honors College, University of Oregon, Eugene, OR

H6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July-August

4 th Year Urology Core Objectives Keith Rourke (Revised June 1, 2007)

Clinical Trial Study Synopsis

CURRICULUM VITAE. Andrea Marraffino, Ph.D.

PACIFIC RESEARCH NETWORK_ 3003 Fourth Avenue, San Diego, CA * (619) Ph. (619) Fax

UTILITY OF NMP22 BLADDERCHEK POINT-OF- CARE ASSAY IN EVALUATION OF HEMATURIA: A MULTICENTER STUDY

Prostate cancer. Treatments Side effects and management in the community setting

UV-2005/01. Chronic Prostatitis and Chronic Pelvic Pain Syndrom (CP/CPPS) Karl-Bickleder-Str. 44C Straubing - Germany

Steven M. Weiner, M.D.

Index. Note: Page numbers of article titles are in boldface type.

Urinary tract disorders

Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia

June 15, Proprietary blending concept for Natural Bladder Support for Women & Men

Victoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine

The Enlarged Prostate Symptoms, Diagnosis and Treatment

Managing urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester

D-MANNOSE, CRANBERRY AND VITAMIN C (CYSTOMAN 100MG) ARE EFFECTIVE IN PREVENTING URINARY TRACT INFECTIONS IN MULTIPLE SCLEROSIS SUBJECTS.

Charles E. Stoopack M.D. FACOG

Asian Urology Residency Course 2017 (AURC 2017)

Society of Academic Urologists AUA Office of Education Report January 21, Victor Nitti, MD Chair, Office of Education

UROLOGY ROTATION SYLLABUS. Level of Training PGY3. Length of Rotation Longitudinal during Geriatric Block Rotation. Preceptors Name(s) and Titles

LUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology

David C. Ragan, M.D Mile High Stadium Circle Denver, CO (office) (fax)

Amy Edmondson Mulroy, MD

Curriculum Vitae. Tampa, FL Tel

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT

Benign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada

UROLOGY. Innovation in Bladder Cancer Treatment CHICAGO ACCESS. How to Refer a Patient. Clinical Trials at UChicago Medicine: Ask Us More Questions!

Curriculum Vitae, Edward H. Ortiz, M.D.

Some prostatic diseases

Asyntomatic bacteriuria, Urinary Tract Infection

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).

The AUA Science & Quality Council. J. Stuart Wolf, Jr., M.D., FACS AUA Science &

Curriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC

A SURVEY ON LOWER URINARY TRACT SYMPTOMS (LUTS) AMONG PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) IN HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)

Summary of Results for Laypersons

Chapter 18: Glossary

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS

Curriculum Vitae, Michael J. Downing, M.D.

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Patient Expectations Following Greenlight XPS

Objectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS

Cooled ThermoTherapy TM

50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?

MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH

Description. Section: Surgery Effective Date: October 15, 2014 Subsection: Surgery Original Policy Date: December 6, 2012 Subject:

Report on New Patented Drugs - Vesicare

The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Paula J. Lane, M.D. Albuquerque Neuroscience, Inc. 101 Hospital Loop NE, Suite 209 Albuquerque, NM 87109

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Abiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC).

CURRICULUM VITAE Robert Brannigan, M.D. Revised : 04/01

ASYMPTOMATIC MICROSCOPIC HEMATURIA IN WOMEN JOLYN HILL, MD ASSISTANT PROFESSOR, CLINICAL UROGYNECOLOGY FEBRUARY14, 2017

APPENDIX CLINICAL INPUT RESPONSES

Posterior Tibial Nerve Stimulation

BPH: a present and future perspective on health impact

Cialis. Cialis (tadalafil) Description

Moving Beyond Cancer To A New Normal in Intimacy For Men & Their Partners. Presented by Mary Ellen West, RN, MN, CNM AASECT Certified Sex Counselor

URINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara

Douglas N. Robins, M.D. Ameriderm Research

DELAYED DIAGNOSIS. Mean time to diagnosis = 4-7 years Mean # of physicians = 8 NIDDK criteria underdiagnoses >60%

New Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital

Chapter 4: Research and Future Directions

Clinical AMG - Studies as Principal Investigator since 2009

An Undergraduate Syllabus for Urology. Produced on behalf of the British Association of Urological Surgeons. March 2012

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

Overactive bladder syndrome (OAB)

Botulinum Toxin: Applications in Urology

2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT

Overview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014

Management of LUTS after TURP and MIT

Prostatitis: overview and assessment of pain outcomes and implications for inclusion criteria. Michel Pontari IMMPACT-XX Meeting July 13, 2017

Cialis. Cialis (tadalafil) Description

Male LUTS, OAB, Sex: natural history. JR Sathiya

West Virginia University School of Medicine, Morgantown, West Virginia

RHONDA Q. FREEMAN, PH.D. SUNRISE MEDICAL GROUP 4925 Sheridan St. Suite 200 Hollywood, FL (954)

Canada Medtronic of Canada Ltd Kitimat Road Mississauga, Ontario L5N 1W3 Canada Tel Fax

Posterior Tibial Nerve Stimulation for Voiding Dysfunction

Curriculum Vitae, David P. Walling, Ph.D. David P. Walling, Ph.D. Collaborative Neuroscience Network, LLC

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

*Compounds with "In-house" in this column include ones discovered by collaborative research.

NOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate

Neurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.

Overactive Bladder: Diagnosis and Approaches to Treatment

Transcription:

David Henry Jablonski, M.D. 1812 North Mills Avenue Orlando, FL 32803 EDUCATION: University of Florida College of Medicine, Gainesville, Florida Division of Urology Residency Training Program July 1994-June 1997 University of Florida College of Medicine, Gainesville, Florida Department of Surgery, General Surgery Residency Training Program July 1992-June 1994 University of Florida College of Medicine, Gainesville, Florida Doctor of Medicine - 1988-1992 University of Virginia, Charlottesville, Virginia Bachelor of Arts in Biology - 1984-1988 WORK EXPERIENCE: Winter Park Urology Associates July 1997 - Present ACADEMIC APPOINTMENTS: Associate Clinical Professor of Surgery University of Florida Division of Urology Clinical Assistant Professor Florida State University School of Medicine Department of Clinical Sciences CERTIFICATION: American Board of Urology, February 1999 Diplomat of National Board of Medical Examiners, July 1993 Florida Board of Medicine #ME0065714 PROFESSIONAL SOCIETIES: Florida Urologic Society American Urologic Association American Medical Association Florida Medical Association

RESEARCH: 2 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of XXXX for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia 2005-present A Multicenter, 2 Week, Double-Blind Study of XXXX 60mg QD Modified Release Capsules and Placebo Given Once Daily In The Morning or In The Evening In Patients With Overactive Bladder 2005-present A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of The Withdrawal Effects of Chronic Daily and As Needed Dosing with Study Drug in the Treatment of Premature Ejaculation 2005-present Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia 2004-present An Open-Label, Multicenter Study To Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg Study Drug in Patients Who Wish to Switch form Detrol LA for the Treatment of Overactive Bladder Symptoms 2004-present A Randomized, Double-Blind, Crossover Study to Evaluate the Duration of Erection following Study Drug 10mg Administration For 4 Weeks in a Fixed-Dose Regimen Compared to Placebo In Males with ED 2004-present A Double-Blind, Randomized, Placebo-Controlled Trial of Elmiron For the Treatment of Chronic, Non-Bacterial Prostatitis 2004-present A Study to Compare the Safety and Efficacy of Once Daily Study Drug Versus Twice Daily Study Drug in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis 2004-present Study of Study Drug in Women of Different Demographic Characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety 2004-present

A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Investigate the Efficacy, Tolerability And Safety of Study Drug Sustained Release in Subjects with Overactive Bladder Syndrome 2003-present A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Study Drug for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy 2003-present A Double-Blind, Placebo-Controlled Study of Frequency and Urgency Using Study Drug 20mg Tablets, Twice Daily, For 12 Weeks Followed by a 6-Month Open-Label Treatment Phase in Patients with Overactive Bladder 2003-2004 A Multicenter, Open-Label, Flexible Dose Study to Investigate the Use Patterns of Viagra (sildenafil citrate) And The Ability of Investigators To Further Optimize Subject Satisfaction With Viagra Through Customized Instruction 2003-present Open-Label Study of the Efficacy and Safety of 5mg and 10mg Study Drug in Patients with Overactive Bladder Symptoms 2003-2004 An Open-Label Study to Evaluate the Efficacy and Safety of Study Drug Administered On Demand to Men of Various Populations with Erectile Dysfunction 2003-2004 A Randomized, Double-Blind, Parallel-Group, Placebo- Controlled Study Evaluating the Efficacy, Safety and Reliability of 20mg Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects with Erectile Dysfunction and a Demonstrated Successful First Response to 20mg Vardenafil 2003-2004 A Double-Blind, Placebo-Controlled, Randomized US/Latin America Study to Evaluate the Effect of Study Drug Prolonged Release on Nocturia in Patients with Symptoms of Overactive Bladder (OAB) 2003-2003 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer 2003-present 3

A Phase 3B, Multi-Center, Double-Blind, Randomized, Placebo- Controlled, Parallel Group Study of XXXXX in Subjects with Overactive Bladder 2002-2003 A Multicenter, Phase IIb, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily of XXXXX in Men with High Grade Prostate Intraepithelial Neoplasia (PIN) 2001-2004 An Open-Label, Multicenter, Multinational Study to Determine the Safety and Efficacy of XXXXX Oral Solution in Children with Symptoms of Urge Urinary Incontinence Suggestive of Detrusor Instability 2002-2003 An Open-label Trial on the Effect of I.V. XXXXX 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis 2002-2003 A Randomized, Double-Blind, Parallel Group, Multi-center Study to Investigate the Time to Onset of Action of 20mg of XXXXX Compared to Placebo in Males with Erectile Dysfunction 2002-2002 A phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of Study Drug for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients. 2001-2003 A Phase IV, Open-label, Multi-Center, Large Community Based Study with an Eight Week Treatment Period to Evaluate the Satisfaction and Experience with Replacement Therapy 2000-2001 A Phase IV, Open-Label, Multicenter, Community-Based Trial of Study Drug for the Treatment of Urogenital Symptoms in Postmenopausal Women 2000-2001 A Patient Acceptability Study of a Once-Daily Formulation of Study Drug. A Phase IIIB, Open-Label, Single-Arm Trial in Adult Patients With Overactive Bladder and Symptoms of Urinary Frequency, Urgency, and/or Urge Incontinence. 2000-2001 4

5 A Multicenter Trial of Induction and 6 Courses of 3 Week Maintenance With BCG Versus BCG Plus Interferon Alfa-2B (Intron A) In Superficial Bladder Cancer 2001-2001 A Multi-center, Multinational Open Clinical Study to Explore Relationships between Genotypic (from DNA) and Serologic (from serum) Findings and Phenotypic Manifestations in a Large Cohort of Participants 2001-2001 A Phase IIb/III Chemoprevention Trial of Study Drug to Prevent the Recurrence of Superficial Bladder Cancer 2001-2002 Prospective, Randomized, Double-Blind Multi-Center, Fixed Dose, Parallel-Group Twelve Month Extension of Study XXXXX to Investigate the Safety and Tolerability of the Study Drug in the Treatment of Patients with Erectile Dysfunction over a Total Exposure Time of 24 Months 2001-2002 A Phase III, Double-Blind, Randomized, Parallel Study Evaluating the Safety and Efficacy of Study Drug in the Treatment of Male Erectile Dysfunction 2001-2002 A Double-Blind, Placebo Controlled Study of Sustained Release Study Drug in Subjects with Symptoms of Overactive Bladder of Urgency, Frequency and Urinary Incontinence - 2001 - Present An Investigation Of The NMP22 Point of Care (POC) Device As An Aid In The Monitoring Of Bladder Cancer Patients. 2001-2002 An Investigation Of The NMP22 Point Of Care (POC) Device As An Aid In The Screening Of Patients At Risk For Bladder Cancer. 2001-2002 A Randomized, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the Safety and Tolerability of a Study Drug in the Treatment of Patients with Erectile Dysfunction - 2000 2001 A Phase III at Home Use Study Evaluating the Efficacy and Safety of Escalating Doses of Study Drug 2, 3, and 4 mg in the Treatment with Erectile Dysfunction 1999 2001 A Study to Evaluate the Efficacy and Safety of a Study Drug Versus Placebo in Subjects with Overactive Bladder - 1999 2001

6 PRESENTATIONS/ PUBLICATIONS A Phase III, Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of a Controlled Release Study Drug Versus A Study Drug in the Treatment of Subjects with Overactive Bladder - 1999 2001 A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study Comparing the Safety, Tolerance, and Efficacy of a Study Drug in Patients with Detrusor Hyperreflexia - 1999 2000 A Phase III, Long-Term, Open-Label, Flexible Dose, and Safety Extension Study of Study Drug in the Treatment of Male Erectile Dysfunction - 1998 1999 A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Study Drug 0.5 Mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia - 1997 2001 A Phase III Efficacy and Safety Study Comparing Escalating Doses of Study Drug to 5 mg or 6 mg Doses of Study Drug or Placebo in the Treatment of Male Erectile Dysfunction 1997-1998 A Study to Evaluate the Impact of Study Drug on Treatment Satisfaction - 1997 1998 "Transurethral Vapertrode Electrovaporization of the Prostate (TUEVP); Physical Principles, Techniques and Results". Submitted to 1997 Southeastern Section and 1997 AUA. Pediatric Hemorrhagic Cystitis: The University of Florida Experience". Presented at the Florida Residence Meeting, San Juan, Puerto Rico, January 1996. PERSONAL: Date of Birth: February 17, 1966 Place of Birth: Grosse Pointe, Michigan Married: Janet Holder Jablonski, M.D. - Family Medicine Updated: 1/2005